ATXN3 and Spinocerebellar ataxia type 3: Recently, our lab showed that befiradol, a potent and highly selective 5-HT1AR agonist, is a promising therapeutic compound for MJD as it rescued motor function and suppressed mutant ATXN3 aggregation in C. elegans [49].